Pulmonx Co. (NASDAQ:LUNG) Director Sells $15,188.78 in Stock

Pulmonx Co. (NASDAQ:LUNG - Get Free Report) Director Glendon E. French III sold 2,326 shares of Pulmonx stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $6.53, for a total value of $15,188.78. Following the completion of the transaction, the director now owns 1,069,648 shares of the company's stock, valued at $6,984,801.44. The trade was a 0.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Pulmonx Stock Performance

LUNG stock traded down $0.07 on Tuesday, hitting $6.19. The company's stock had a trading volume of 100,331 shares, compared to its average volume of 233,769. Pulmonx Co. has a 1 year low of $5.46 and a 1 year high of $14.84. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a market cap of $244.44 million, a price-to-earnings ratio of -4.21 and a beta of 0.66. The firm has a 50 day moving average of $6.45 and a two-hundred day moving average of $6.89.

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its earnings results on Wednesday, October 30th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. The business had revenue of $20.39 million during the quarter, compared to analysts' expectations of $20.39 million. During the same period in the prior year, the company earned ($0.39) earnings per share. Equities analysts predict that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Institutional Trading of Pulmonx

Hedge funds have recently added to or reduced their stakes in the stock. Parkman Healthcare Partners LLC acquired a new position in shares of Pulmonx during the third quarter worth about $1,711,000. State Street Corp boosted its holdings in Pulmonx by 2.6% in the 3rd quarter. State Street Corp now owns 747,028 shares of the company's stock valued at $6,193,000 after purchasing an additional 18,592 shares in the last quarter. Squarepoint Ops LLC increased its position in Pulmonx by 261.2% during the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company's stock worth $916,000 after purchasing an additional 104,432 shares during the period. Polar Asset Management Partners Inc. purchased a new position in shares of Pulmonx during the 3rd quarter worth approximately $893,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Pulmonx by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 892,786 shares of the company's stock valued at $7,403,000 after buying an additional 11,151 shares during the period. 91.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LUNG has been the subject of several analyst reports. Stifel Nicolaus lowered their price target on shares of Pulmonx from $17.00 to $16.00 and set a "buy" rating for the company in a report on Thursday, October 31st. Wells Fargo & Company lowered their target price on shares of Pulmonx from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Wednesday, December 11th. Finally, Citigroup restated a "neutral" rating and issued a $7.50 price target (down from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $12.75.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.